12/7/2020 8:09:41 AM
Lyra Therapeutics Announces Positive Topline Results From LANTERN Phase 2 Study Of LYR-210 For Chronic Rhinosinusitis
8/4/2020 8:09:36 AM
Lyra Therapeutics Announces Pamela Nelson As SVP Of Regulatory Affairs
7/7/2020 8:36:47 AM
Lyra Therapeutics Appoints Robert Richard SVP Of Research And Development
5/5/2020 10:02:31 AM
Lyra Therapeutics Announces Closing Of IPO